<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011166</url>
  </required_header>
  <id_info>
    <org_study_id>2355-004</org_study_id>
    <secondary_id>IDX-08C-004</secondary_id>
    <nct_id>NCT01011166</nct_id>
  </id_info>
  <brief_title>Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin in Subjects With Genotype 1 Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess short term safety, antiviral activity and pharmacokinetics (PK) of
      IDX184 in combination with Peg-interferon (Peg-IFN)/Ribavirin (RBV) in participants with
      hepatitis C virus (HCV) genotype (GT) 1 infection. These data will guide dose selection for
      future, longer term studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HCV ribonucleic acid (RNA) level from Baseline to Day 15</measure>
    <time_frame>Baseline and Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing adverse events (AEs)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing serious adverse events (SAEs)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing Grade 1-4 laboratory abnormalities</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HCV RNA level from Baseline to Day 28</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with undetectable HCV RNA at Day 15</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with undetectable HCV RNA at Day 28</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing virologic breakthrough while on study therapy</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alanine aminotransferase (ALT) level from Baseline to Day 15</measure>
    <time_frame>Baseline and Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT level from Baseline to Day 28</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the drug concentration-time curve (AUC) from time 0 to last measurable concentration (AUC0-t)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to infinity (AUC0-~)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed terminal half-life (Thalf)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>IDX184 50 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo once daily (QD) in combination with Peg-IFN/RBV on Days 14-28 and Peg-IFN/RBV on Days 14-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 100 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 100 mg BID + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo twice daily (BID) in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 150 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized 4:1 (active:placebo) to receive IDX184 150 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 200 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 200 mg BID + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized 4:1 (active:placebo) to receive IDX184 200 mg or placebo BID in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX184</intervention_name>
    <description>IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.</description>
    <arm_group_label>IDX184 50 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg BID + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 150 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 200 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 200 mg BID + Peg-IFN/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo white opaque capsules taken by mouth from Day 1 to Day 14.</description>
    <arm_group_label>IDX184 50 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg BID + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 150 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 200 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 200 mg BID + Peg-IFN/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2a (Peg-IFN)</intervention_name>
    <description>Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.</description>
    <arm_group_label>IDX184 50 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg BID + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 150 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 200 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 200 mg BID + Peg-IFN/RBV</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.</description>
    <arm_group_label>IDX184 50 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg BID + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 150 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 200 mg QD + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 200 mg BID + Peg-IFN/RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has documented chronic HCV GT1 infection

          -  Agrees to use of double-barrier contraception and males agree not to donate sperm from
             the first dose of study therapy through at least 6 months after the final dose of
             study therapy

        Exclusion Criteria:

          -  Has received previous antiviral treatment for HCV infection

          -  Has cirrhosis or decompensated liver disease

          -  Is pregnant or breastfeeding

          -  Is co-infected with hepatitis B virus (e.g., hepatitis B surface antigen [HBsAg]
             positive) and/or human immunodeficiency virus (HIV)

          -  Has clinically significant concomitant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Lalezari J, Box T, O'Riordan W, Mehra P, Nguyen T, Poordad F, Dejesus E, Kwo P, Godofsky E, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D. IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C. Antivir Ther. 2013;18(6):755-64. doi: 10.3851/IMP2552. Epub 2013 Feb 25.</citation>
    <PMID>23439365</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>HepC</keyword>
  <keyword>Hep C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

